Connect with us


CBD and CBG have ‘significant’ anti-inflammatory effect in the lungs

The first results from a study into the impact of cannabinoids on respiratory diseases have been published



CBD and CBG in combination were found to have ‘significant anti-inflammatory activity’ in the lungs.   
Listen to this article

Researchers have found that the cannabinoids CBD and CBG, when used in combination, are beneficial for treating inflammation in the lungs.

Scientists at King’s College London, working in collaboration with Sativa Wellness Group have published the first results from a study into the impact of cannabinoids on respiratory diseases.

It aimed to investigate the anti-inflammatory effects of the two non-psychotropic cannabinoids alone and in combination, in a model of pulmonary inflammation. 

According to a statement released by the company, the results of the work suggest that the CBD and CBG in combination have ‘significant anti-inflammatory activity’ in the lungs.   

This builds on previous research suggesting cannabinoids are promising potential treatments for inflammatory diseases. 

The research also identified that the formulation for administering cannabinoids is critically important to obtain efficacy.

Concluding, the authors wrote: “This study has provided evidence that CBD and CBG formulated appropriately exhibit anti-inflammatory activity. 

“Our observations suggest that these non-psychoactive cannabinoids may have beneficial effects in treating diseases characterised by airway inflammation.”

Sativa Investments PLC announced that it had entered into a research agreement with King’s College London to study the impact of cannabinoids on inflammation and respiratory diseases in 2019.

Geremy Thomas, executive chairman said: “We have actively supported research now for over two years to identify the therapeutic benefits cannabinoids can have on medical conditions. Research is something we as a company believe is essential to inform the public and we are delighted to have seen such positive results identified.”

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister titles, Cannabis Wealth and Psychedelic Health.Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained.She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa.Sarah Sinclair is the editor of Cannabis Health. Got a story? Email / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag